Antipyretic TRIZ Cases

A pyridine-based pharmaceutical compound suppresses collagen production by inhibiting the TGF-β-Smad signaling pathway.

Engineered antibody CDR sequences neutralize IL-6 activity, resolving incomplete disease control in rheumatoid arthritis.

Engineered variable regions resolve non-specific inhibitor trade-offs by blocking ligand binding without competing IL-34 interaction.

Surfactant-drug complexes anchor lipophilic agents on balloons, preventing premature loss during delivery while maintaining controlled release.

TyrRS protein variants expose the ELR motif through structural separation of catalytic and C-terminal domains.

A human CDR-grafted antibody binds the extracellular region of CCR4 to deplete target cells.

Isolated IMP cells target damaged tissue repair while reducing off-target side effects from high cell doses.

A3 adenosine receptor agonists resolve the contradiction between opioid efficacy and addiction liability by activating distinct pain pathways.

Red lettuce generates high polyphenol levels through phenylpropanoid pathway regulation and plant eustressor application.

A biodegradable drug depot film delivers analgesic agents directly to the surgical site for sustained pain management.

Optimizing SHR0302 topical formulations with controlled pH and dimethyl sulfoxide concentrations prevents API crystal formation during storage.

Amino acid composition with thickener agents converts muscle hypercatabolism to anabolic activity.

Engineered cysteine residues enable selective thiol-maleimide coupling, resolving product uniformity issues while preserving antibody stability.

SOS1 and Ras inhibitors target the NGF pathway to relieve pain without opioid addiction risks.

Ectoine and hydroxyectoine formulations resolve mucous membrane dehydration by replacing high-salt solutions that draw water from tissues.

Specific amino acids enhance barrier integrity and reduce inflammation without immunosuppressive risks.

Xylitol combined with anionic polymers creates shear thinning viscosity, resolving stickiness trade-offs in intra-articular injections.

Specific Fc region mutations create pH-dependent FcRn binding, extending serum half-life while preserving therapeutic efficacy.

Segmented triterpenoid structures with specific functional groups enhance anti-inflammatory activity while maintaining structural diversity.

A covalent complex links antigens to antibody CDR2 residues, stabilizing therapeutic polypeptides without biological activity loss.

A betaine eutectic solvent mixture enables ambient temperature extraction of natural biological materials.

Sarilumab addresses insufficient quality of life improvements by significantly elevating SF-36 scores across pain, vitality, and fatigue domains.

Administering an anti-CHL1 antibody during acute inflammation delays tissue repair to prevent irreversible fibrosis.

Modified lipid compounds reduce cholesterol and triglyceride levels through targeted structural parameter changes.

Engineered IgG2 hinge mutations lock antibody conformation to elicit specific agonistic or antagonistic properties.

Targeting TG2 transamidase activity reduces fibroblast extracellular matrix deposition, addressing scleroderma side effects from broad immunosuppression.

Targeted residue modifications in antibody variable regions preserve antigen binding affinity while reducing immunogenicity caused by non-human framework mismatches.

Adipose-derived stromal cells reduce pro-inflammatory cytokines to treat moderate rheumatoid arthritis.

Mixed Atractylodes Rhizome white and Taraxacum Herba extract inhibits inflammatory responses in biological systems.

Diazine and triazine compounds inhibit interferon-gamma, TNF-alpha, and interleukins to reduce inflammatory severity.

Human monoclonal antibodies bind CXCR4 to block SDF-1 signaling, inhibiting tumor metastasis while avoiding side effects from non-specific inhibitors.

Genetic knockout of IL2 production and IL6 antagonist expression in modified immune cells prevents fatal cytokine release syndrome during adoptive cell therapy.

Grapefruit essential oil decreases IL-3 gene expression, inhibiting myeloma cell growth and osteoclast activation while delaying disease progression.

A transdermal patch coated with Cymbopogon citratus, Zanthoxylum armatum, and Hedychium spicatum oils delivers active ingredients through the skin.

Transforming amorphous BTK inhibitor Compound 1 into stable crystalline forms resolves handling difficulties and improves formulation reliability.

Multimodal opioid-free analgesic formulations combine local anesthetics, COX inhibitors, and NMDA antagonists to reduce postoperative nausea and vomiting.

AS1 benzamide compounds reverse noxious stimulus valence, alleviating chronic pain and anxiety.

Integrin alpha10-selected mesenchymal stem cells modulate immune responses to treat respiratory disorders.

Monoclonal antibodies block IL-31 signaling pathways to resolve inflammatory responses in atopic dermatitis patients.